Circio fundamentale forhold (CRNA, tidl. TRVX)

[solskimm]

En liten tikkeliste på hva vi kan forvente oppdatering på etterhvert:

• ONCOS 102 plattform med 2x Fast Track Designations og best in class x2

  • Melanoma NewsWeb

    • Studieoppsett
    • Partner for CPI / CTLA-4 inhibitor
    • Første pasient dosert

  • Mesothelioma - ASCO-poster 2022

    • Hva er veien videre?

• TG, Agenus, mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULONT

  • TG indikasjon 1 : RAS mutant multiple myeloma, NewsWeb , 20 pasienter
    • Finansiert via offentlige tilskudd
    • Studieoppsett
    • Første pasient
  • TG indikasjon 2
  • TG indikasjon 3

• Next gen virus preklinisk

• CRNA preklinisk

• Pågående studie i colorectal (samarbeid uten kostnad, i kombinasjon med AstraZeneca, Cancer Research Institute (CRI) og Ludwig Cancer Research)

  • Oppdateres på ASCO 2022

• IOVAXIS Therapeutics, TG01/02, potensiell utlisensieringsavtale for Kina

  • Venter på oppdatering, potensielt 30mill upfront
  • Utvidelse av programmet til resten av verden?

• VALO Therapeutics, oppdatering samarbeid, ONCOS-102,

• OBLIQUE Therapeutics, oppdatering samarbeid, Oncolytic virus w/ mutRAS
  antibody payload

• Leidos checkpoint inhibitor functionality to ONCOS viruses

• Zelluna Immunotherapy, FTO license to intellectual property relating to mutant RAS T cell receptor technology

• Papyrus Therapeutics, ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality

  • PYTX-003 Oppdatering H1 23

Er det noe jeg har glemt eller er feil så gi meg beskjed så oppdaterer jeg

*Edit: Oppdatert med ASCO-postere på Meso og colorectal.
*Edit 2: oppdatert med TG-indikasjon 1 av 3

[TekBot]

Targovax ASA: Registration of share capital increases following exercise of options

Oslo, 8 March 2022: Reference is made to the stock exchange announcement by
Targovax ASA (“Targovax” or the “Company”) on 2 March 2022, regarding the board
of directors’ resolutions to increase the share capital of the Company in
…

Vis børsmeldingen

connection with the exercise of employee options and RSUs.

The share capital increases have today been registered with the Norwegian
Register of Business Enterprises (Nw.: Foretaksregisteret). The Company’s new
share capital is NOK 18,842,242.10, divided into 188,422,421 shares, each with a
par value of NOK 0.10.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Kilde

[TekBot]

Targovax ASA: Poster presentation at the AACR Annual Meeting

Oslo, Norway, 9 March 2022 - Targovax ASA (OSE: TRVX), a clinical stage immuno
-oncology company developing immune activators to target hard-to-treat solid
tumors, today announces that an abstract has been accepted for poster
…

Vis børsmeldingen

presentation at the American Association for Cancer Research (AACR) Annual
Meeting.

The abstracts show ONCOS-102 drives pro-inflammatory modulation of the tumor
micro-environment in PD-1 refractory melanoma tumors. ONCOS-102 is associated
with efficient viral gene expression and strong, sustained activation of immune
-related genes, which may be targets for future combinations of ONCOS-102 and
immune-modulators beyond PD-1/PD-L1 inhibitors.

The abstract has been released on the AACR website today
(Abstracts | AACR Annual Meeting 2022 | April 8-13, 2022 | New Orleans). The poster
is scheduled for presentation Monday 11 April 2022 and will be available on
Targovax’s website (https://www.targovax.com/en/oncos-oncolytic-virus
-publications-posters-and-oral-presentations/) after the presentation.

Poster Modulation of immune gene expression by intra-tumoral oncolytic
title: adenovirus ONCOS-102 is associated with clinical response in anti
-PD-1 refractory/resistant melanoma
Date and Monday 11 April 2022, 13:30- 17:00 CDT / 20:30-24:00 CET
time:
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section
31
Session Clinical research excluding trials
category:
Session Immune response to therapies / immune monitoring and clinical
title: correlate
Poster 1983
number:
Presenter: Thomas Birkballe Hansen, VP Research, Targovax

About AACR

The AACR Annual Meeting is the focal point of the cancer research community,
where scientists, clinicians, other health care professionals, survivors,
patients, and advocates gather to share the latest advances in cancer science
and medicine. From population science and prevention; to cancer biology,
translational, and clinical studies; to survivorship and advocacy; the AACR
Annual Meeting highlights the work of the best minds in cancer research from
institutions all over the world.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Kilde

[TekBot]

Targovax ASA: Annual Report 2021

On 9 March 2022, the Board of Directors of Targovax ASA approved the Company’s
Annual Report, including the financial statements for 2021, which will be
processed at the Company’s annual general meeting on 20 April 2022. Targovax ASA
…

Vis børsmeldingen

also publishes today its annual financial statements in the European Single
Electronic Format (ESEF), which is available as an attachment to this release.

The documents are also available at the Company’s website,
www.targovax.com (Financial Reports – Targovax).

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Kilde

[TekBot]

Targovax - Proposal to implement a drop-down demerger

Lysaker, 14 March 2022: The Board of Directors of Targovax has today, on 14
March 2022, signed a joint demerger and merger plan, respectively, for the
transfer of the operational activities of the Company to its wholly-owned
…

Vis børsmeldingen

subsidiary, Targovax Solution AS.

The transfer is proposed carried out as a “drop-down demerger” where the Company
demergers operations and assets to its subsidiary Athomstart Invest 586 AS.
Immediately after the demerger, Athomstart Invest 586 AS merges with the
Company’s wholly owned subsidiary, Targovax Solution AS, whereby the merger
consideration is issued in the Company and corresponds to the share capital
decrease amount in the Company in connection with the Demerger.

The background for the proposed drop-down demerger is that the Board of
Directors finds it desirable to establish a pure group structure, with separate
operating companies rather than having operations in the listed parent company.

On this basis, the Board of Directors will propose that the Annual General
Meeting to be held on 20 April 2022 approves the demerger and merger plan, with
their respective appendices, both dated 14 March 2022, in addition to adopting
the other corporate resolutions that are required in order to implement the drop
-down demerger.

The demerger plan for the demerger and the merger plan for the merger with their
respective appendices, both dated 14 March 2022, will be available at the
Company’s website www.targovax.com (https://www.targovax.com/en/annual-general
-meeting-2022/) later today pursuant to section 8 of the articles of
association.

The drop-down demerger is expected to be completed during June 2022, subject to
the approval by the Annual General Meeting.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.

Kilde

[anon99889496]

Kan se ut som forberedelse til salg av et lem eller?

[Sjakk]

Tja ikke sak tenker jeg, er vel mer å rydde litt, rett og slett at topp selskapet/holdingen bør være fritt for operasjonell støy, og fokuserer på å drifte datterselskapene sine. Er om det som da ligger i holdingen faktisk er noe som risikerer å bli verdt noe og splittes ut og fusjoneres ned i et datterselskap før det faktisk blir verdt så mye at det blir kostbart å tukle med det (skatteteknisk)

edit: nå fikk jeg litt mer gullpenge vibber. Sjekket struktur, og de har jo ikke en asa holding med underselskaper! så dette er en fisjon ned i et datterselskap… (jada det står i meldingen, jeg innbildte meg at det var fisjonering av noe skrot i ASA/topp selskapet, ut i separat selskap og fusjon inn i et eksisterende datterselskap) Dette blir ny struktur og blodpumpa fikk litt mer fart her

[TekBot]

Notice of Annual General Meeting

The Annual General Meeting of Targovax ASA (the “Company”) will be held at the
Company’s offices at Lysaker, on 20 April 2022 at 16:00 CET.

…

Vis børsmeldingen

Notice of attendance

Notice of attendance must be received no later than 19 April 2022 at 16:00 CET.

Casting of advance votes and submission of proxies must be received no later
than 19 April 2022 at 16:00 CET.

Attached you will find the notice to the General Meeting, including appendices.
The notice and appendices will also be made available on Targovax’ website
General Meetings – Targovax.

TRVX - Notice AGM
20.04.2022.pdf (https://mb.cision.com/Public/17093/3535332/b74086509936d02f.pdf)

For further information, please contact:
Lubor Gaal, CFO
Phone: +34 683 343 811
Email: lubor.gaal@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.

Kilde

[TekBot]

Targovax ASA: Minutes from the Annual General Meeting

The annual general meeting was held on 20 April 2022 at the Company’s offices at
Vollsveien 19, 1366 Lysaker.

…

Vis børsmeldingen

Please find minutes of the meeting attached:

2022 Targovax ASA AGM
minutes.pdf (https://mb.cision.com/Public/17093/3549223/b330c957fe038019.pdf)

---

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.

Kilde

[TekBot]

Targovax ASA: Issuance of restricted stock units (RSUs) to the board members

Reference is made to the annual general meeting of Targovax ASA (the “Company”)
on 20 April 2022 (the “AGM”) where election of members to the board of directors
was according to the nomination committee’s proposal. At the same AGM of the
…

Vis børsmeldingen

Company the board of directors was authorized to extend the Company’s restricted
stock unit (“RSU”) program and to issue RSUs to the board members. The RSUs are
non-transferable and each RSU gives the right and obligation to acquire one
share in the Company at a price of NOK 0.10 per share (corresponding to the
nominal value of the shares) subject to satisfaction of the applicable vesting
conditions.

If the board members choose to receive the board remuneration in RSUs they must
elect to either (i) receive 100% of the compensation in RSUs, (ii) receive 1/3
of the compensation in cash and 2/3 in RSUs, or (iii) receive 2/3 of the
compensation in cash and 1/3 in RSUs. The number of RSUs is calculated on the
basis of a board remuneration of NOK 525 000 to the chairperson of the board and
NOK 310,000 to the other board members, divided by the market price of the
Company’s shares calculated as the volume weighted average share price for the
10 trading days prior to the AGM being NOK 1.79 per share.

Damian Marron has resolved to receive 1/3 of the board remuneration, as
determined by the Company’s annual general meeting in 2022, in the form of RSUs
and the board of directors has resolved to issue 97,765 RSUs to Damian Marron.
Damian Marron holds 141,753 RSUs, no options and no shares in the Company.

Eva-Lotta Allan has resolved to receive 1/3 of the board remuneration, as
determined by the Company’s annual general meeting in 2022, in the form of RSUs
and the board of directors has resolved to issue 57,728 RSUs to Eva-Lotta Allan.
Eva-Lotta Allan holds 98,539 RSUs, no options and 71,368 shares in the Company.

Diane Mellett has resolved to receive 1/3 of the board remuneration, as
determined by the Company’s annual general meeting in 2022, in the form of RSUs
and the board of directors has resolved to issue 57,728 RSUs to Diane Mellett.
Diane Mellett holds 115,949 RSUs, no options and 96,029 shares in the Company.

Sonia Quaratino has resolved to receive 2/3 of the board remuneration, as
determined by the Company’s annual general meeting in 2022, in the form of RSUs
and the board of directors has resolved to issue 115,456 RSUs to Sonia
Quaratino. Sonia Quaratino holds 138,178 RSUs, no options and no shares in the
Company.

Thomas Falck has resolved to receive 2/3 of the board remuneration, as
determined by the Company’s annual general meeting in 2022, in the form of RSUs
and the board of directors has resolved to issue 115,456 RSUs to Thomas Falck.
Thomas Falck holds 115,456 RSUs, no options and no shares in the Company.

Raphael Clynes has resolved to receive 2/3 of the board remuneration, as
determined by the Company’s annual general meeting in 2022, in the form of RSUs
and the board of directors has resolved to issue 115,456 RSUs to Raphael Clynes.
Raphael Clynes holds 115,456 RSUs, no options and no shares in the Company.

Notification by Primary Insiders_Marron AGM RSU
(20.04.22).pdf (https://mb.cision.com/Public/17093/3549740/bac1d8a7e99b746c.pdf)

Notification by Primary Insiders_Falck AGM RSU
(20.04.22).pdf (https://mb.cision.com/Public/17093/3549740/b03e31814e690d85.pdf)

Notification by Primary Insiders_Allan AGM RSU
(20.04.22).pdf (https://mb.cision.com/Public/17093/3549740/a4078141496ec9f6.pdf)

Notification by Primary Insiders_Quaratino AGM RSU
(20.04.22).pdf (https://mb.cision.com/Public/17093/3549740/900038e2353c883f.pdf)

Notification by Primary Insiders_Mellett AGM RSU
(20.04.22).pdf (https://mb.cision.com/Public/17093/3549740/97693b9b7dcb19b1.pdf)

Notification by Primary Insiders_Clynes AGM RSU
(20.04.22).pdf (https://mb.cision.com/Public/17093/3549740/9096bb0e6944b320.pdf)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.

Kilde

[Frs2904]

Hvorfor velger 3 av 6 styremedlemmer å ta honoraret i 1/3 aksjer og resten kontanter. Ingen av styremedlemmene valgte 100 % aksjer? Dette gir et tydelig signal om at optimismen ikke er på topp.

[Frs2904]

Alle har vel sin vanlige jobb - styrevervene er vel stort sett tilleggsinntekt? Når de som sitter nærmest selskapet ikke satser mer, så sier det vel alt. Gir et lite tillitsvekkende signal til markedet. Det er tross alt de som sitter nærmest informasjonen.

[anon99889496]

@Frs2904

Når de som sitter nærmest selskapet ikke satser mer, så sier det vel alt.

No må du gi deg det der er direkte misvisende.

[TekBot]

Targovax ASA announces the appointment of two new Board Directors

Oslo, Norway, 21 April 2022 - Targovax ASA (OSE: TRVX) announces that the
General Meeting has elected Dr Raphael Clynes and Mr Thomas Falck as new members
of its Board of Directors.
…

Vis børsmeldingen

Dr Clynes
Dr Clynes is an internationally recognized cellular immunologist and medical
oncologist. Dr Clynes was on the faculty at the Columbia University where he
developed several novel therapeutic approaches in cancer and autoimmunity. Since
joining industry in 2014, Dr Clynes has led clinical immunotherapy development,
including checkpoint inhibtors and novel CD3 bispecifics, at Bristol Myers
Squibb (BMS) and at Xencor, where he is currently VP Translational Biology.

Dr Clynes is an MIT graduate and MSKCC-trained medical oncologist. As a well
-recognized expert in clinical immunology, Dr Clynes has extensive prior
experience as a contributing member of multiple scientific advisory boards in
biopharma and review boards at international research foundations.

Mr Falck
Mr Falck is an experienced CEO, CFO, Board Chair and Non-Executive Director,
Venture Capitalist & Growth Investor with demonstrated success in defining and
delivering profitable growth while undertaking strategic and organizational
change. He has broad experience with Private Equity, Venture Capital, Stock
Listed, Family and Government owned entities.

Mr Falck holds an MBA from The Darden School at the University of Virginia and
is a graduate of the Norwegian Naval Academy and the Norwegian Defence
University College. In addition, Mr Falck has attended Executive Programs at
Singularity University and Harvard Business School.

The Chairman of Board of Directors, Mr Damian Marron says: “We are very pleased
to have attracted both Dr Clynes and Mr Falck as new members of the Board. Dr
Clynes is a world-leading expert in immuno-oncology and his deep expertise in
translational medicine will be instrumental as we push ONCOS-102 forward in the
clinic and build our portfolio of next generation circular RNA pipeline
candidates. Mr Falck is an experienced NED & Board Member, Investor, Advisor &
Tech Executive, and whose strategic insight will be of great value for the
Board.”

Raphael Clynes and Thomas Falck are replacing Per Samuelsson and Johan
Christenson. Targovax expresses the company’s gratitude for the excellent work
both has done as members of the Board over many years.

---

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.

Kilde

[Birgitte]

Dette er feil ressonement. Disse bruker en del av sine løpende inntekter til å investere i selskapet. Det er positivt.

[Profit]

Det er vel ikke så vanlig å ta styrehonorar i aksjer. Det blir å snu problemstillingen litt på hodet. Dette er forskere og nerder , og ingen spekulanter.

[TekBot]

Targovax to present at 5th Neoantigen Summit Europe in Amsterdam

Oslo, 26 April 2022 - Targovax ASA announces that members of its executive
management team are invited for oral presentations and a panel discussion at the
5[th] Neoantigen Summit Europe in Amsterdam 27-28 April.
…

Vis børsmeldingen

Presentation: Uncovering the Benefits of Personalized Vaccines in a Clinical
Setting
Presenter: Dr. Erik Digman Wiklund (CEO)
Date: 27 April 2022
Time: 10:00 CET

Presentation: Clinical Combination Strategies with Oncolytic Vaccines in Solid
Tumors
Presenter: Dr. Victor Levitsky (CSO)
Date: 28 April 2022
Time: 15:30 CET

Panel Discussion: Evaluating Combination Therapies to Maximize Anti-Tumour
Immune Activity
Participants from Targovax: Erik Digman Wiklund (CEO), Victor Levitsky (CSO)
Date: 28 April 2022
Time: 16:00 CET

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.

Kilde

[TekBot]

Targovax ASA: Two ONCOS-102 abstracts accepted for ASCO

Oslo, Norway, 28 April 2022 - Targovax ASA (OSE: TRVX), a clinical stage immuno
-oncology company developing immune activators to target hard-to-treat solid
tumors, today announces that two ONCOS-102 abstracts have been accepted for
…

Vis børsmeldingen

poster presentation at the American Society of Clinical Oncology (ASCO) Annual
Meeting in Chicago 3-7 June 2022.

The abstracts will be released on the ASCO website 26 May 17:00 CEST
(https://meetings.asco.org/meetings/2022-asco-annual-meeting/288/program
-guide/scheduled-sessions). The posters are scheduled for presentation during
the ASCO congress 3 - 7 June 2022.

Poster Final survival outcomes and immune biomarker analysis of a
title: randomized, open-label, phase I/II study combining oncolytic
adenovirus ONCOS-102 with pemetrexed/cisplatin (P/C) in patients
with unresectable malignant pleural mesothelioma (MPM)
Presenter: Dr Santiago Ponce, Medical Oncology, Hospital 12 Octubre, Madrid,
Spain

Poster Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic
title: durvalumab in patients with peritoneal disease who have epithelial
ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2
results
Presenter: Dr Dmitriy Zamarin, Memorial Sloan Kettering Cancer Center, New
York, USA

---

About ASCO

American Society of Clinical Oncology Annual Meeting, ASCO 2022 will be held in
McCormick Place, Chicago, Illinois, United States between 03 - 07 June 2022.

The 2022 ASCO Annual Meeting Program will offer presentations on the latest
research in cancer care. This year’s program will feature sessions complementing
the meeting’s theme: Advancing Equitable Cancer Care Through Innovation.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.

Kilde

[TekBot]

Targovax ASA: Invitation to presentation of Targovax’s first quarter 2022 results, Thursday 12 May

Oslo, Norway, 3 May 2022 - Targovax ASA (OSE: TRVX) will announce its first
quarter 2022 results on Thursday 12 May 2022. An online presentation by
Targovax’s management to investors, analysts and the press will take place at
…

Vis børsmeldingen

10:00 am CET.

The results report and the presentation will be available at
www.targovax.com (Financial Reports – Targovax) in the
Investors section from 07:00 am CET.

Presentation

There will be a virtual presentation of the results with a live webcast 12 May
at 10.00 am CET. You can join the webcast
here (https://channel.royalcast.com/landingpage/hegnarmedia/20220512_8/). It
will be possible to ask questions during the presentation.

---

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.

Kilde

[TekBot]

Targovax and Oslo University Hospital announce collaboration to test TG mutant RAS vaccination in multiple myeloma

· Targovax has entered into an agreement with Oslo University Hospital (OUS) to
test TG01 in a phase 1/2 trial in 20 patients with RAS mutant multiple myeloma
· The trial will be sponsored by OUS and led by Dr. Fredrik Schjesvold, an
…

Vis børsmeldingen

international leader in the field and founder of the Oslo Myeloma Center, the
largest Myeloma center in the Nordics
· The trial will be the first time TG vaccination is tested in patients
together with the new adjuvant QS-21 STIMULONT from collaboration partner Agenus

Oslo, Norway, 10 May 2022 - Targovax ASA (OSE: TRVX), a clinical-stage immuno
-oncology company developing immune activators to target hard-to-treat solid
tumors, today announces that it has entered into a clinical trial collaboration
agreement with Oslo University Hospital (OUS) to run a phase 1/2 study testing
polyvalent mutant RAS vaccine TG01 in multiple myeloma (MM) following standard
of care (SoC) therapy.

Oncogenic mutations in the RAS family of genes drive up to 30% of all cancers
and remain a major unmet medical need with few good treatment alternatives.
Targovax was recently awarded two prestigious research grants from Innovation
Norway and the Norwegian Research Council, totaling NOK 18m, to advance its TG
mutant RAS cancer vaccine program. These grants include funding towards several
clinical studies, of which the first to open will be a TG01 phase 1/2 trial in
MM patients with relevant KRAS and NRAS mutations (approx. 15-20% of MM
patients) to be run in Oslo, Norway.

The trial is a collaboration between OUS and Targovax and will test TG01
vaccination as a monotherapy in 20 KRAS or NRAS mutated MM patients who continue
to have measurable disease after completion of SoC treatment. The aim is to
assess whether anti-RAS T-cell priming induced by TG01 can enhance the clinical
response. OUS will sponsor and be responsible for running and funding the trial,
with Dr. Schjesvold as the principal investigator. Targovax will provide TG01
drug supply, scientific support and financial contribution.

Dr. Fredrik Schjesvold, Founder and Leader Oslo Myeloma Center, at Oslo
University Hospital, and President of the Nordic Myeloma Study Group, said: “RAS
-mutant multiple myeloma has poor prognosis and there are currently no available
targeted treatment options for this patient population. Prior data clearly
demonstrates the capability of TG01 to induce robust anti-RAS T-cell responses
and eliminate residual disease in cancer patients, and suggest that TG
vaccination could be a valuable tool to deepen and prolong responses in multiple
myeloma. Being a Norwegian product makes it particularly interesting, and we
very much look forward to collaborating with Targovax to test this concept in
practice at our center.”

Earlier in 2022, Targovax announced a collaboration with Agenus to utilize their
proprietary vaccine adjuvant QS-21 STIMULONT as an immune-stimulatory component
of the TG vaccines for future development and commercialization. QS-21 has
consistently demonstrated powerful antibody and cell-mediated immune responses
both in cancer trials and commercially as a component of the Shingrix[®] and
MosquirixT vaccines. QS-21 should further potentiate the TG vaccines by driving
stronger anti-RAS T-cell responses. The OUS trial will be the first study in
patients of TG01 adjuvanted by QS-21.

Dr. Erik Digman Wiklund, Chief Executive Officer of Targovax ASA, added:
“Following promising data from the first generation TG01 vaccine in pancreatic
cancer, we have focused on enhancing our mutant RAS platform and establishing a
cost-efficient, collaborative development plan to bring the program forward. We
are now ready to bring TG01 back into the clinic in a new and improved format
and are excited to work with Dr. Schjesvold and his team to assess the potential
of TG01 in multiple myeloma. This trial will be the first step in a broader
exploratory program with multiple collaboration partners aimed at testing TG01
vaccination in various RAS mutant cancer types and treatment combinations.”

---

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax’s focus is to
activate the patient’s immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable
safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both as monotherapy and in
immunotherapy and chemotherapy combinations, the next development step for ONCOS
-102 will be to further improve immune activation and clinical response in
melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and
providing deep mechanistic insights, Targovax is expanding its ONCOS program
into delivery of circular RNA and targeting KRAS mutant cancers with the aim of
establishing a platform for development of a rich pipeline of innovative future
immunotherapy product candidates.

Kilde